Stevanato Group S.p.A. (NYSE:STVN) Shares Acquired by Pier Capital LLC

Pier Capital LLC boosted its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 381,624 shares of the company’s stock after purchasing an additional 10,627 shares during the quarter. Pier Capital LLC owned approximately 0.13% of Stevanato Group worth $8,316,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Van Berkom & Associates Inc. acquired a new position in shares of Stevanato Group in the 4th quarter valued at about $39,000. PNC Financial Services Group Inc. lifted its holdings in Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after acquiring an additional 5,291 shares during the last quarter. US Bancorp DE boosted its stake in Stevanato Group by 17.9% in the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock valued at $186,000 after acquiring an additional 1,295 shares during the period. Marco Investment Management LLC bought a new position in shares of Stevanato Group during the fourth quarter valued at approximately $203,000. Finally, Hardy Reed LLC raised its position in shares of Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after purchasing an additional 840 shares during the period.

Stevanato Group Price Performance

Shares of NYSE:STVN opened at €22.34 ($24.02) on Tuesday. The stock has a market cap of $6.77 billion, a price-to-earnings ratio of 47.53, a PEG ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 12 month low of €16.56 ($17.81) and a 12 month high of €33.49 ($36.01). The stock’s 50 day moving average price is €21.04 and its 200 day moving average price is €20.59.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Equities research analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on STVN shares. Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective for the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Bank of America upped their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, UBS Group decreased their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of €27.75 ($29.84).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.